Happy Friday everyone and thanks for joining me on this scary journey of writing a book especially now that over 130 of you have subscribed for updates the pressure is really on…. 😱 I will try to stay consistent and every Friday write a brief on one of the chapters I am planning to put in the book so if you have any insights, thoughts, comments, or even anecdotes please feel free to reach out - (you can chose if you want to be quoted in the book 😂)
I will take you back to 2016: I just recently joined a large pharmaceutical and that November went to the first Frontiers Health conference taking place in Berlin. There I watched in awe Riccardo Sabatini who at the time was chief scientist at Human Longevity and in that talk I was first introduced to the “EROOM Law”
In short - EROOM law (opposite of MOORE’s Law) shows that finding those drug(able) targets is getting more and more difficult with rapidly declining R&D productivity.
https://www.nature.com/articles/nrd3681
While data shows that biomolecular innovation have contributed to an amazing rise in our human longevity already, the EROOM law and hence our deeper understanding of biology over time is certainly been driving much more customized and personalized approach to health.
During the twentieth century, U.S. life expectancy at birth increased by almost 30 years(63%), from 47.3 years in 1900 to 77.0 years in 2000. — Source: [https://journals.uio.no/NJHE/article/download/1290/1177/]
The focus (and the cash cow) of the pharmaceutical industry is of course molecules so optimizing the R&D productivity and reversing the downward spiral is #1 priority? Will one of over 150 (and counting) “magic #AI in drug discovery” startups help pharma sustain its pipeline, reduce costs and time to market with better outcomes? Is the current success of the industry preventing it being even more successful? If you have something to say about the above, reach out
Till next week,